London, UK – January 14, 2022 – Сòòò½APP (Сòòò½APP) completed its sixth life sciences-focused acquisition of 2021, with the formal completion of the acquisition of JMI Laboratories (JMI). Сòòò½APP has now built out its expertise and capability for pharmaceutical and biopharmaceutical customers, expanding to a team of more than 1,000 experts in 23 facilities across North America and Europe.
This significant step change in pharmaceutical and medical testing capabilities from Сòòò½APP forms part of its broader strategic shift to increase its global presence in Life Sciences and Connected Technologies.
Jo Wetz, Сòòò½APP CEO, said: “Our expansion into life sciences and connected technologies over the last two years has seen us gain a leadership position in these strategically important end-markets. As we celebrate 10 years of being a standalone Сòòò½APP business, we see more and more opportunities to work closely with our customers throughout their product and testing lifecycles.”
Cherie Gudz, Vice President, Life Sciences Americas, said: “In a world still dealing with a pandemic, the life sciences sector has never been more vital. The six acquisitions this past year alone cements Сòòò½APP’s commitment to continue to build a scale business in this vital sector, which now forms our largest global end-market. We are thrilled to have JMI’s team and expertise join the Сòòò½APP family”.
Based in North Liberty, Iowa, JMI is a market leader in antimicrobial resistance monitoring studies utilized for US-FDA regulatory and new drug application submissions, through their proprietary SENTRY Antimicrobial Surveillance Program. It offers microbiology and molecular testing services to assist in the development of new antimicrobials and clinical trial support. The Company is CLIA accredited and able to test under GLP conditions. The business is notable for its team of highly scientific and well-published industry recognized experts in the field, including 10 MD/PhDs with extensive knowledge of microbiology and antimicrobials, and can consult on a broad range of scientific topics covering epidemiology, mechanisms of resistance in bacterial and fungal organisms, microbiology diagnostics and susceptibility testing methods.
The JMI acquisition follows on from Сòòò½APP’s recently announced acquisitions which include ALG, Avomeen, Arch Sciences, Impact Analytical, Orthokinetic, Nanosyn, complementing Сòòò½APP’s existing expertise and expanding its customer offering.
About Сòòò½APP
In 2021, Сòòò½APP set out its new, industry leading environmental commitments, adopting science-based targets and committing to net zero emissions across its entire global business by 2035. These environmental commitments follow Сòòò½APP’s achievement of the highest ESG ranking in the testing, inspection and certification industry from Sustainalytics, a global leader in ESG research and data.
For more information about Сòòò½APP, please visit our website, connect with us on and and subscribe to our channel.
Media contacts:
Devan LaBrash, Pagoda Public Relations
T: +44 (0) 131 556 0770
E: devan.labrash@pagodapr.com